Sign In
Buy BEAM
$25.52
-0.97 (-3.66%)
At Close: Jul 31, 2026
Beam Therapeutics (NASDAQ:BEAM) Insider Christine Bellon Sells 5,956 Shares
05:40am, Tuesday, 07'th Apr 2026
Beam Therapeutics Inc. (NASDAQ: BEAM - Get Free Report) insider Christine Bellon sold 5,956 shares of Beam Therapeutics stock in a transaction on Wednesday, April 1st. The stock was sold at an average
Beam Therapeutics (NASDAQ:BEAM) Insider Amy Simon Sells 6,700 Shares
05:40am, Tuesday, 07'th Apr 2026
Beam Therapeutics Inc. (NASDAQ: BEAM - Get Free Report) insider Amy Simon sold 6,700 shares of the business's stock in a transaction dated Wednesday, April 1st. The shares were sold at an average pric
Beam Therapeutics (NASDAQ:BEAM) President Giuseppe Ciaramella Sells 11,810 Shares
05:07am, Tuesday, 07'th Apr 2026
Beam Therapeutics Inc. (NASDAQ: BEAM - Get Free Report) President Giuseppe Ciaramella sold 11,810 shares of the company's stock in a transaction that occurred on Wednesday, April 1st. The stock was so
SG Americas Securities LLC Acquires 60,249 Shares of Beam Therapeutics Inc. $BEAM
05:32am, Saturday, 04'th Apr 2026
SG Americas Securities LLC lifted its stake in shares of Beam Therapeutics Inc. (NASDAQ: BEAM) by 139.4% in the undefined quarter, according to the company in its most recent filing with the Securitie
Prestigious Publication Reinforces risto-cel's Durable, Differentiated Clinical Data for the Treatment of SCD with Severe Vaso-occlusive Crises (VOCs)
Beam Therapeutics’ BEAM-302 Hits Protective AAT Levels in AATD; 60 mg Picked for Pivotal in H2 2026
02:34am, Friday, 27'th Mar 2026
Beam Therapeutics (NASDAQ: BEAM) executives and clinical collaborators presented updated top-line data from the company's ongoing Phase I/II study of BEAM-302, an in vivo base-editing therapy being ev
BEAM Eyes Global Expansion of AATD Study After Strong Early Data
12:10pm, Thursday, 26'th Mar 2026
Beam Therapeutics reports promising phase I/II data for BEAM-302 in AATD, showing strong efficacy, tolerability and potential as a one-time curative treatment.
Beam Therapeutics Inc. (BEAM) Discusses Topline Phase I/II Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency Transcript
10:15pm, Wednesday, 25'th Mar 2026
Beam Therapeutics Inc. (BEAM) Discusses Topline Phase I/II Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency Transcript
Beam Therapeutics Gains On Clinical Update As Gene Therapy Hits Protective Protein Levels
10:31am, Wednesday, 25'th Mar 2026
BEAM-302 is Beam's lead genetic disease program for liver-targeting therapy for alpha-1 antitrypsin deficiency (AATD) that addresses the underlying pathophysiology of both liver and lung disease.
Treatment with 60 mg of BEAM-302 Led to Mean Steady-state Total AAT Level of 16.1 µM and All Patients Consistently and Durably Above the 11 µM Protective AAT Threshold with up to 12 Months of Follow
Beam Therapeutics Inc. (NASDAQ:BEAM) Receives Consensus Rating of “Moderate Buy” from Analysts
02:44am, Friday, 20'th Mar 2026
Shares of Beam Therapeutics Inc. (NASDAQ: BEAM - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the sixteen ratings firms that are covering the firm, MarketBeat repor
Beam Therapeutics Stock Surges 23% in 6 Months: What's Driving It?
12:31pm, Thursday, 12'th Mar 2026
BEAM shares jump 23% in six months as upbeat risto-cel data, pipeline expansion and new financing strengthen confidence in its gene-editing strategy.
Beam Therapeutics: Great Potential, But Patience Is Needed
09:40am, Friday, 27'th Feb 2026
Beam Therapeutics Inc. is rated a Buy for its leadership in proprietary base-editing gene therapy, targeting significant unmet needs in hematology and liver diseases. BEAM's risto-cel shows superior e
BEAM's Q4 Loss Narrower Than Expected, Revenues Rise Y/Y
12:06pm, Wednesday, 25'th Feb 2026
Beam Therapeutics posts a narrower Q4 loss as revenues surge past estimates. It secures $500M financing, extending its cash runway into mid-2029.
Beam Therapeutics Inc. (BEAM) Q4 2025 Earnings Call Transcript
04:57pm, Tuesday, 24'th Feb 2026
Beam Therapeutics Inc. (BEAM) Q4 2025 Earnings Call Transcript
